akash.verma@cenmed.com
(732) 447-1115-
L333143-50mga selective and potent p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. -
L333143-25mga selective and potent p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. -
L333143-250mga selective and potent p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. -
L333143-10mga selective and potent p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. -
L333143-100mga selective and potent p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. -
-
-
-
-
-
L133844-25mgLatanoprost (free acid) is a metabolite of Latanoprost, an F-series prostaglandin (PG) analog which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester, a prodrug form which is converted to latanoprost (free -
L133844-100mgLatanoprost (free acid) is a metabolite of Latanoprost, an F-series prostaglandin (PG) analog which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester, a prodrug form which is converted to latanoprost (free
